Abstract
Immunotherapy is revolutionizing the treatment of non-small cell lung cancer (NSCLC). Programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) monoclonal antibod-ies have recently led to significant and durable improvements in the clinical outcome of NSCLC, and the anti-PD-1 antibody has been approved to use in first-line and second-line treatment of NSCLC. However, there are still many problems to be solved. The role of PD-L1 as a predictive biomarker remains unclear. Combination treatment models are being explored. This review summarizes the clinical efficacy, drug adverse reaction, combined treatment, and potential immune biomarkers of anti-PD-1/PD-L1 antibody research progress in the treatment of NSCLC. Key words: Membrane glycoproteins/TU; Antibodies, monoclonal/TU; Carcinoma, non-small-cell lung/TH; Immunotherapy; Review
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
